AbClon Inc. (KOSDAQ: 174900)

Market Cap	235.70B
Revenue (ttm)	2.40B
Net Income (ttm)	-18.18B
Shares Out	17.59M
EPS (ttm)	-1,112.61
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	45,512
Average Volume	55,267
Open	13,400
Previous Close	13,400
Day's Range	13,180 - 13,510
52-Week Range	10,830 - 22,150
Beta	0.06
RSI	39.40
Earnings Date	n/a

About AbClon

AbClon Inc. engages in the research and development of antibody drugs in South Korea and Sweden. The company’s products in pipeline include NEST platform technology products for breast and gastric cancers; AffiMab platform technology products for colon cancer and autoimmune diseases; and CAR-T platform technology products for hematologic and ovarian cancers. AbClon Inc. was founded in 2010 and is based in Seoul, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2010
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 174900

Financial Performance

In 2023, AbClon's revenue was 3.08 billion, a decrease of -9.50% compared to the previous year's 3.41 billion. Losses were -12.92 billion, 39.6% more than in 2022.